Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C, Chronic Kidney Disease
Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
- Trial name
- NCT02503735
- Testing
- Sofosbuvir/Ledipasvir FDC
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, Hepatitis C
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
Infection with either HIV or hepatitis C virus (HCV) affects immune system responses. The purpose of this study is to investigate the immune responses to two different vaccine formulations in HIV-infected, HCV-infected, and…
- Trial name
- NCT00393276
- Testing
- Twinrix, Decavac
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Chronic Hepatitis c
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic…
- Trial name
- NCT01903278
- Testing
- PEG-IFN-SA /RBV, Pegasys /RBV
- Where
- 41 sites in China
- Volunteers
- 719 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis C
A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
The study will assess the efficacy of PPI-668 (USAN: ravidasvir hydrochloride) in combination with sofosbuvir, with or without ribavirin, in the following Egyptian HCV gt-4 patient populations: 1.
- Trial name
- NCT02371408
- Testing
- ravidasvir hydrochloride, sofosbuvir, ribavirin
- Where
- 3 sites in Egypt
- Volunteers
- 300 people
- Sponsor
- Pharco Pharmaceuticals
Hepatitis
A Controlled Prospective Study of Transfusion-Associated Hepatitis
This protocol represents a continuation of a series of prospective studies to define the incidence and etiology of transfusion-associated hepatitis (TAH) and to examine the impact on TAH of various modifications in the selection…
- Trial name
- NCT00004848
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Interferon (IFN)-based therapy is the treatment of choice for HCV infection for HIV coinfected patients…
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection
- Trial name
- NCT04768517
- Where
- 7 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
HCV Infection
Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
Hepatitis C (HCV) is a chronic infection with significant morbidity and mortality. The development of directly acting antivirals (DAA) has dramatically improved the cure rate of HCV treatment.
- Trial name
- ECLIPSE (NCT04235049)
- Testing
- Glecaprevir/pibrentasvir
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
HIV, Hepatitis C
Behavioral Science Aspects of Rapid Test Acceptance
The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Syphilis
- Trial name
- BSARTA (NCT01317784)
- Testing
- Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- California State University, Long Beach
Hepatitis C, HCV
Hepatitis C Treatment in Probation and Parole Office
This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P\&P office) setting and compare…
- Trial name
- NCT05413785
- Testing
- Telehealth in Parole/Probation Office
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Jens Rosenau
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Phase I Trial of Silymarin for Chronic Liver Diseases
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
- Trial name
- SyNCH (NCT00389376)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
HIV Infections, Hepatitis C
Prevalence of Hepatitis C Virus Infection in HIV-Infected Children
The purpose of this study is to find out how many children who are infected with HIV are also infected with hepatitis C virus (HCV). HCV infection is a major health concern.
- Trial name
- NCT00037076
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Virus
A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
The purpose of this study was to evaluate the efficacy, safety and pharmacokinetics of ABT-450/r when given together with ABT-267 and with and without RBV in treatment-naïve participants with genotype 1, 2 or 3 chronic HCV…
- Trial name
- Navigator (NCT01458535)
- Testing
- ABT-450, ABT-267, ribavirin
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C
Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China
The proposed study will investigate the knowledge level, attitudes, and perceptions among staff of Methadone Maintenance Treatment (MMT) clinics and intravenous drug users (IDUs) who attending MMT clinics, which is the most…
- Trial name
- NCT01647191
- Testing
- intervention group, control group
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Shanghai Mental Health Center
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered…
- Trial name
- NCT04382404
- Testing
- Sofosbuvir-Velpatasvir Drug Combination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Catherine Anne Chappell
Hepatitis C, Chronic
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche…
- Trial name
- NCT00800735
- Testing
- Pegylated-interferon alfa-2a, Ribavirin
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to…
- Trial name
- NCT00192647
- Testing
- PEG-IFN alfa-2a, Ribavirin
- Where
- 51 sites in Argentina, Australia and 4 more
- Volunteers
- 896 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus
Acceptance and Feasibility of Hepatitis c Screening Strategies in Social Insertion Centers
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease worldwide. It is a progressive disease that without treatment leads to the development of cirrhosis in approximately 10-20% of patients.
- Trial name
- TGSS_CIS (NCT05756738)
- Testing
- Dried blood spot testing
- Where
- Spain
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- University of La Laguna
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT04155515
- Testing
- TG-2349, DAG181, Ribavirin
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Chronic Hepatitis C
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.
- Trial name
- NCT00227435
- Testing
- val-mCyd
- Where
- 4 sites in United States
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.